Boehringer Ingelheim’s weight-loss drug candidate survodutide could also be effective for liver disease metabolic dysfunction-associated steatohepatitis (MASH), if the res
GSK has reported topline results from a phase 3 trial of its novel antibiotic gepotidacin that could spell the end of a decades-long drought in new oral therapies for gono
Sanofi has not had the success it was hoping for with its oral BTK inhibitors, acquired as part of its $3.7 billion buyout of Principia Biopharma, but can now point to a w
I have spent the last 15 years working in rare diseases, working with some of the most dedicated ambassadors for rare disease, from researchers to patient advocates to patients and families
AstraZeneca has moved a step closer to EU approval of oral Factor D inhibitor danicopan in the EU, after the EMA’s human medicines committee, the CHMP, backed the drug as
Views & Analysis
White Papers & Webinar
Podcasts & Video
The industry has been calling for a disease-agnostic event fully dedicated to the exciting new modality of peptide-based drugs.
A brand-new event has just launched in the renowned World ADC Series – the inaugural ADC Payload Summit is taking place
According to the FDA, 2024 will be the ’breakout year’ for gene therapies.
In the dynamic cell therapy landscape, where financial challenges continue to prevail, the emphasis on innovative process development becomes pivotal.